SNDL Inc SNDL.OQ reported a quarterly adjusted loss of 7 cents per share for the quarter ended September 30. The lone analyst forecast for the quarter was for a loss of 5 cents per share.
Revenue was $236.89 million; analysts expected $232.40 million.
SNDL Inc's reported EPS for the quarter was a loss of 7 cents.
SNDL Inc shares had risen by 4.9% this quarter and gained 31.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for SNDL Inc is 3.50
This summary was machine generated from LSEG data November 6 at 04:59 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -0.05 | -0.07 | Missed |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.